Abstract 3665
Background
L provided a 19.4 month (mo) median PFS in the phase 3 Study of Lenvatinib in Differentiated Cancer of the Thyroid (SELECT) and an objective response rate of 60.2%; however, all patients (pts) experienced some toxicity. In Canada, a PSP was created to offer L to pts with rDTC prior to public funding. We report the prescription practices and treatment patterns of these pts.
Methods
Between August 2015 and January 2019, 223 pts with rDTC started L as part of the PSP. Prescriber information, patient demographics, start and discontinuation dates, starting doses and dose modifications and reasons for discontinuation were ascertained whenever possible. Pt and prescriber demographic and clinical characteristics were described using summary statistics. Kaplan-Meyer method was used to estimate persistency on L, defined as time from first prescription to discontinuation.
Results
Two-hundred twenty-three rDTC pts were analyzed (42% female, mean age 63.4 years). Median study follow-up was 15.8 mo. Mean starting dose was 21.2mg and was 24 mg for 158 pts (66%), 20mg for 35 pts (15%) and lower for 47 pts. Median KM estimate of persistency on L was 15.8 mo and was similar for pts starting full or reduced dose. Treatment persistency was similar between all provinces but there was a trend favouring prescribers with more than one patient in the PSP versus those with only one patient (18.0 mo vs 10.2 mo, p = 0.0922) and for pts treated by endocrinologists compared to other specialties. There was also a trend for longer persistency in pts who had dose modifications compared to pts treated with constant doses (19.0 mo vs 9.8 mo, p = 0.0577). One hundred and twelve pts have discontinued L (39 deaths from disease, 23 progressive disease/palliation, 15 for medical reasons other than toxicity (including decision to pursue alternative therapy), 14 from toxicity and 21 undisclosed/other reasons).
Conclusions
To date, this is the largest presented real-world analysis of the treatment patterns of L in pts with rDTC and our estimates of treatment duration as proxy for effectiveness are comparable to the phase 3 SELECT trial. Toxicity led to a minor proportion of discontinuations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Eisai Supported the Patient Support Program, hosted by Innomar Strategies, Inc.
Disclosure
S.J. Hotte: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Eisai. E. Winquist: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Eisai. N. Chua: Honoraria (self), Advisory / Consultancy: Eisai. J..D. Ruether: Honoraria (self), Advisory / Consultancy: Eisai. N. Lamond: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Eisai. S. Ezzat: Advisory / Consultancy: Eisai. M. Massicotte: Honoraria (self), Advisory / Consultancy: Eisai. R. Wong: Advisory / Consultancy: Eisai. P. Lam: Full / Part-time employment: Eisai. B. Yap: Full / Part-time employment: Eisai. M.K. Krzyzanowska: Honoraria (self), Research grant / Funding (institution): Eisai; Research grant / Funding (institution): Exilixis. All other authors have declared no conflicts of interest.
Resources from the same session
4991 - Relation between objective tumor shrinkage and progression-free survival (PFS) in the NETTER-1 population
Presenter: Marianne Pavel
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Abstract
5796 - Phase I Study of CC-90011 in Patients With Advanced Solid Tumors (STs) and Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)
Presenter: Antoine Hollebecque
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Abstract
3199 - SUNitinib with EVOfosfamide (TH-302) for G1/G2 metastatic pancreatic neuroendocrine tumours (pNETs) naïve for systemic treatment. The SUNEVO phase II trial of the Spanish Task Force Group for Neuroendocrine and Endocrine Tumours (GETNE)
Presenter: Enrique Grande
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Abstract
Slides
5891 - New circulating biomarkers in Gastro-Entero-Pancreatic-Neuroendocrine-Tumors
Presenter: Martine Bocchini
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Abstract
1590 - Longitudinal Increase in Ki67 and High-grade Transformation in Pancreatic Neuroendocrine Tumors (PNETs)
Presenter: Johan Botling
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Abstract
3362 - Impact of lung metastasis on overall survival (OS) in the phase 3 SELECT study with lenvatinib (LEN) in patients (pts) with radioiodine refractory differentiated thyroid cancer (RR-DTC)
Presenter: Makoto Tahara
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Abstract
5072 - Spatiotemporal intratumor genetic heterogeneity and clonal evolution in PTCs and paired DM
Presenter: Sara Gil Bernabé
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Abstract
2034 - Specific patterns of long non-coding RNA expression in benign and malignant thyroid nodules
Presenter: Valentina Yakushina
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Abstract
Poster Discussion – NETs and endocrine tumours - Invited Discussant 1382PD, 1383PD and 1834PD
Presenter: Nicola Fazio
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Slides
Webcast
Poster Discussion – NETs and endocrine tumours - Invited Discussant 1385PD and 1386PD
Presenter: Rocio Garcia-Carbonero
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Slides
Webcast